Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small firms left vulnerable in wake of UK "home-brew" ruling

This article was originally published in Clinica

Executive Summary

Clinical laboratories in the UK are reeling from shock following the open publication by the Medicines and Healthcare Products Regulatory Agency of two letters dictating the need to CE mark some IVDs that are made in-house that put at risk thousands of "home-brew" IVDs. It seems that most laboratories were totally unaware until they read the MHRA's statements of the fact that the IVD Directive applied to them and are now rushing to establish where they stand and what rules they need to comply with.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel